Study: Growth factor inhibitors market to triple

April 7, 2004

An aging patient population and diseases such as macular degeneration will boost the worldwide market for drugs that inhibit growth factors and angiogenesis from under $4 billion to more than $13 billion in the next five years, according to a study released March 24 by an independent market research firm.